Premium
The role of pleiotropic effects of statins in dementia
Author(s) -
Crisby M.
Publication year - 2006
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2006.00695.x
Subject(s) - reductase , pathogenesis , cholesterol , statin , dementia , hmg coa reductase , cholesterol synthesis , medicine , in vivo , pharmacology , very low density lipoprotein , hydroxymethylglutaryl coa reductase , alzheimer's disease , enzyme , coenzyme a , disease , endocrinology , chemistry , lipoprotein , biochemistry , biology , microbiology and biotechnology
High serum cholesterol is associated with ischemic heart disease. Recent reports also indicate that cholesterol modulates amyloid beta‐peptide interactions in the brain. Statins are inhibitors of 3‐hydroxy‐3‐methylglutaryl‐Coenzyme A reductase (HMG‐CoA reductase), the rate‐limiting enzyme involved in cholesterol synthesis. Statin treatment significantly reduces the levels of low‐density lipoproteins (LDL) and very low‐density lipoproteins (VLDL). In the past decade, cardiovascular mortality and morbidity has been reduced by the use of statins. However, evidence from in vivo and in vitro research has indicated that statins may confer multiple effects because of the inhibition of the production of intermediates in the mevalonate pathway. The aim of this review was to discuss the biological effects of statins on regulation of processes involved in the pathogenesis of dementia.